TVTX 250117 10.00C (TVTX250117C10000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

TVTX250117C10000

Watchlist

7.85
0.000.00%

15min DelayTrading Jan 13 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

News

Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $45
Moomoo NewsJan 14 07:31 ET · Ratings
Express News | Travere Therapeutics Inc : Guggenheim Raises Target Price to $45 From $41
ReutersJan 14 06:38 ET
Stifel Maintains Travere Therapeutic(TVTX.US) With Hold Rating
Moomoo NewsJan 13 20:31 ET · Ratings
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $24
Moomoo NewsJan 13 16:32 ET · Ratings
Express News | Travere Therapeutics Inc: Expects Fiscal Year 2024 Net Product Sales to Be Approximately $227 Mln
ReutersJan 13 07:05 ET
Express News | Travere Therapeutics Inc: On Track to Provide Regulatory Update on Sparsentan in Fsgs by Its Q4 2024 Earnings Call
ReutersJan 13 07:05 ET

Comments

Jaguar8

Nov 4, 2024 13:02

NEWS 13G

$Travere Therapeutic (TVTX.US)$
Travere Therapeutic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.02%)

Stock_Drift

Oct 26, 2024 08:40

Earnings on 10/31 👻🎃

$Travere Therapeutic (TVTX.US)$

MMu

Oct 17, 2024 13:03

$Travere Therapeutic (TVTX.US)$ They got the europe approval as well! When is the next event date? @anyone

MMu

Oct 14, 2024 14:06

$Travere Therapeutic (TVTX.US)$
Someone buying large blocks 150k, 50k....
Does anybody know what's going on?

Jaguar8

Sep 26, 2024 15:03

NEWS

$Travere Therapeutic (TVTX.US)$
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). The voluntary enrollment pause enables the Company to work to address ...